98%
921
2 minutes
20
Background: Recently, early graft loss has become very rare in living-related kidney transplantation (LKT) as a result of decreased risk of hyperacute rejection and improvements in immunosuppressive regimens. Post-transplant acute thrombotic microangiopathy (TMA) is a rare, multi-factorial disease that often occurs shortly after kidney transplantation and is usually resistant to treatment with dismal renal outcomes. The complement genetic variants may accelerate the development of TMA. However, the complement genetic test was seldom performed in unknown native kidney disease recipients scheduled for LKT.
Case Presentation: We reported three cases of unknown native kidney diseases who had fulminant TMA in the allograft shortly after LKT. Both the donors and the recipients were noted to carry complement genetic variants, which were identified by genetic testing after transplantation. However, all recipients were refractory to treatment and had allograft loss within 3 months after LKT.
Conclusion: This case series highlights the suggestion to screen complement gene variants in both the donors and the recipients with unknown native kidney diseases scheduled for LKT.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284761 | PMC |
http://dx.doi.org/10.1186/s12882-022-02868-7 | DOI Listing |
Int Urol Nephrol
September 2025
Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Purpose: Living donor kidney transplantation is a critical strategy to address the growing burden of end-stage kidney disease (ESKD) in Malaysia. Whilst living donation is generally safe, concerns remain regarding long-term donor outcomes. This study aimed to evaluate renal function and morbidity changes in living kidney donors 1 year post-donation, and to identify predictors of impaired kidney function.
View Article and Find Full Text PDFWorld J Urol
September 2025
Department of Urology and Transplantation Surgery, Nantes University Hospital, Nantes, France.
Purpose: In 5-10% of cases, renal cancer extends into the venous system, particularly the inferior vena cava (IVC), which worsens prognosis. This study aims to assess morbidity, mortality, and oncological outcomes of patients treated surgically for renal cancer with IVC extension over a 30-year period, in two experienced centers.
Materials And Methods: This bicentric, retrospective study analyzed patients treated between 1988 and 2020 for renal cancer involving the IVC.
Kidney Int
September 2025
Department of Inflammation and Immunity, Lerner Research Institute, Cleveland, Ohio, USA; Transplant Center, Cleveland Clinic, Cleveland, Ohio, USA. Electronic address:
Kidney Int
September 2025
Immunopathology Research Laboratory, Department of Pathology, Boston, Massachusetts, USA; Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
Background: Cytomegalovirus (CMV) viremia is a critical concern and known by the presence of the virus DNA in the blood, which poses sever risks and develops many complications in immuno-compromised patients. When CMV is untreated, it can cause pneumonitis, colitis, hepatitis, and encephalitis. Current diagnosis relies on molecular methods with qPCR as the preferred method.
View Article and Find Full Text PDF